Medicines Formulary New additions and changes

Latanoprost (Lotacryn) preservative free multidose bottles - Added as SpA. Lotacryn is a cost effective alternative with a reduced carbon footprint compared to the unit dose vials. Unit dose vials will remain on the formulary for patients unable to switch. These are the multidose bottles that have been approved with their associated CO2 savings:

	Current CO2	Proposed CO2	CO2 Saving*
BIMI (Bimatoprost 0.3 mg/ml) 3ml (1 month bottle) 9ml (3 months bottle)	172.38 Kg	37.35 Kg	135.03 Kg 405.09 Kg
DIMAZ (Dorzolamide 20 mg/ml)	301.09 Kg	32.62 Kg	268.47 Kg
CODIMAZ (Dorzolamide 20 mg/ml + Timolol 5 mg/ml)	302.75 Kg	32.80 Kg	269.95 Kg
Lotacryn (Latanoprost 50 micrograms/ml)	*1051.27 Kg*	*227.77 Kg*	*823.49 Kg*
TOTAL	1827.48 Kg	330.54 Kg	1,496.94 Kg

Heylo - is leakage notification system, for people with an ileostomy, or colostomy with a liquid or mushy output. Stakeholders felt it was more important to address the cause of the leaking stoma or ileostomy. It has therefore been designated as **non-formulary DNP.**

Adult ADHD shared care and transfer of care agreement – ELFT – Amber SCG. This agreement only covers Luton and Bedfordshire patients under the care of East London Foundation Trust. The existing SCG has been reviewed and updated.

Aymes ActaGain Protein Shot is a new high protein product for oral and tube fed patients which is more cost effective than the alternative, ProSource. ActaGain Protein Shot was approved for use as **SpA,** second line dietitian only recommended product for patients requiring protein supplementation via oral or enteral routes if Protifar is not appropriate. ProSource products will remain on the formulary for patients unable to tolerate ActaGain Protein Shots. The dietitians at Milton Keynes hospital will be actively switching patients off ProSource and Aymes ActaGain will be provided to patients on discharge.

Combination antidiabetic tablets were considered by the group due to misalignment of status across the formularies. They have been designated as **non-formulary DNP**.

Biosimilar Ustekinumab - Ustekinumab is on the local formularies and in use in line with NICE TA recommendations in moderate to severe psoriasis, active psoriatic arthritis, active Crohn's disease and active ulcerative colitis At launch, ustekinumab biosimilars are not licensed for ulcerative colitis. The proposal to add the Pyzchiva and Wezenla biosimilars as **red** drugs to the formularies was approved.

Mexiletine. Newly licensed generic mexiletine 50mg, 100mg and 200mg capsules have been added to the formulary for the treatment of ventricular arrhythmias as **red** drugs for specialist prescribing only.

The following medicines were noted as being **de-branded:**

- **Vipidia®** name has been removed from alogliptin (patent still in place), manufactured by Takeda.
- **Salazopyrin®** name has been removed from Sulphasalazine – now generic, manufactured by Pfizer.
- **Ralvo®** name has been removed from Lidocaine patches – now generic, manufactured by Grunenthal.